EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Recombinant Hypoallergenic Cat Allergy Vaccines

Daria Trifonova, Mirela Curin, Margarete Focke-Tejkl, Zicheng Liu, Kristina Borochova, Pia Gattinger, Marianne van Hage iD, Hans Grönlund iD, Renata Kiss, Huey-Jy Huang, Walter Keller iD, Ksenja Riabova und 6 weitere

Allergy · 2025

DOI: 10.1111/all.16542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von Daria Trifonova und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Infectiology, and Immunology, Medical Un…. Hauptthemen laut MEDLINE: Vaccines, Synthetic, Hypersensitivity, Cats, Allergens. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Worg Pharmaceuticals, Danube Allergy Research Cluster of the Country of Lower Austria, Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molecular forms of allergen‐specific immunotherapy (AIT) for cat allergy are needed. Fel d 1, Fel d 4, and Fel d 7 are the most important cat allergens.

Methods

IgE epitopes of Fel d 4 and Fel d 7 were mapped by blocking allergic patients' IgE binding with allergen peptide‐specific antisera. Five recombinant fusion proteins (PreS‐Cat 1‐PreS‐Cat 5) each containing hepatitis B virus (HBV)‐derived PreS as an immunological carrier and non‐allergenic peptides from the IgE binding sites of Fel d 1, Fel d 4, and Fel d 7 were expressed in Escherichia coli , purified, and characterized by mass spectrometry, circular dichroism (CD), and size exclusion chromatography. ImmunoCAP and basophil activation experiments demonstrated the hypoallergenic activity of PreS‐Cat 1–5. The ability of PreS‐Cat 1–5 to induce IgE‐blocking antibodies in rabbits was compared to three licensed allergen extract‐based AIT vaccines. PreS‐Cat 1‐5‐specific IgG antibodies were tested for inhibition of allergen‐specific IgE binding and specific basophil activation. T cell activation and induction of specific cytokine secretion by PreS‐Cat proteins were compared with cat allergens in PBMC cultures.

Results

Recombinant hypoallergenic, biochemically and structurally defined PreS‐Cat 1–5 were obtained. Two subcutaneous immunizations of rabbits with PreS‐Cat 1–5 induced equal (Fel d 1) or better (Fel d 4 and Fel d 7) antibodies (PreS‐Cat 5 > PreS‐Cat 1 > PreS‐Cat 3) blocking allergic patients' IgE binding to cat allergens than six to fifteen immunizations with allergen extract‐based vaccines. PreS‐Cat‐specific antibodies strongly inhibited specific basophil activation. PreS‐Cat 5 > PreS‐Cat 1 induced significantly more IL‐10 in cultured PBMCs from cat allergic patients than cat allergens.

Conclusions

PreS‐Cat 5 and PreS‐Cat 1 are highly promising molecular vaccine candidates for AIT of cat allergy, combining Fel d 1‐, Fel d 4‐, and Fel d 7‐peptides in single PreS fusion proteins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, SyntheticHypersensitivityCatsAllergensDesensitization, ImmunologicHumansAnimalsRecombinant Fusion ProteinsRabbitsImmunoglobulin EEpitope MappingGlycoproteinsLipocalins

Stichwörter der Autor:innen

allergenallergen‐specific immunotherapy (AIT)allergycat allergymolecular allergy vaccine

Substanzen

Vaccines, SyntheticFel d 1 protein, Felis domesticusFel d 4 allergen, Felis domesticusAllergensRecombinant Fusion ProteinsImmunoglobulin EGlycoproteinsLipocalins

Autor:innen und Institutionen

  • Department of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, Vienna, Austria.
  • LIFE Improvement by Future Technologies (LIFT) Center, Skolkovo, Moscow, Russia.
  • Department of Medicine Solna, Division of Immunology and Respiratory Medicine and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
  • Therapeutic Immune Design Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Center for Molecular Allergology, Karl Landsteiner University for Healthcare Sciences, Krems, Austria.
  • Institute of Molecular Biosciences, BioTechMed Graz, University of Graz, Graz, Austria.

ORCID-Profile: Marianne van Hage, Hans Grönlund, Walter Keller, Rudolf Valenta

Förderung

  • Worg Pharmaceuticals
  • Danube Allergy Research Cluster of the Country of Lower Austria
  • Russian Science Foundation
  • Region Stockholm (ALF Project)
  • Swedish Asthma and Allergy Association's Research Foundation
  • Swedish Heart-Lung Foundation

Zitieren

APA

Trifonova, D., Curin, M., Focke-Tejkl, M., Liu, Z., Borochova, K., Gattinger, P., van Hage, M., Grönlund, H., Kiss, R., Huang, H. J., Keller, W., Riabova, K., Karsonova, A., Kundi, M., Tulaeva, I., Fomina, D., Karaulov, A., & Valenta, R. (2025). Recombinant Hypoallergenic Cat Allergy Vaccines. Allergy. https://doi.org/10.1111/all.16542

Vancouver

Trifonova D, Curin M, Focke-Tejkl M, Liu Z, Borochova K, Gattinger P, et al. Recombinant Hypoallergenic Cat Allergy Vaccines. Allergy. 2025. doi:10.1111/all.16542

BibTeX
@article{Trifonova2025,
  author = {Trifonova, Daria and Curin, Mirela and Focke-Tejkl, Margarete and Liu, Zicheng and Borochova, Kristina and Gattinger, Pia and van Hage, Marianne and Grönlund, Hans and Kiss, Renata and Huang, Huey-Jy and Keller, Walter and Riabova, Ksenja and Karsonova, Antonina and Kundi, Michael and Tulaeva, Inna and Fomina, Daria and Karaulov, Alexander and Valenta, Rudolf},
  title = {Recombinant Hypoallergenic Cat Allergy Vaccines},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16542}
}
Kostenlos starten →